MapLight Therapeutics (MPLT) director sells shares to cover tax obligations

Rhea-AI Filing Summary

MapLight Therapeutics director Robert C. Malenka sold shares of voting common stock mainly to cover taxes tied to equity awards. On February 10, 2026 he sold 6,622 shares at a weighted average price of $18.12, and on February 11, 2026 he sold 241 shares at $18.00.

According to the footnotes, these sales were made to satisfy tax obligations upon settlement of restricted stock units. After the transactions, he directly owned 351,370 shares of voting common stock and indirectly held 31,672 shares through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power.

The remaining securities are still subject to a lock-up agreement related to MapLight Therapeutics’ initial public offering, under which he agreed, with certain exceptions, not to sell or transfer shares for 180 days following the final prospectus dated October 26, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malenka Robert C.

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/10/2026		S		6,622(1)	D	$18.12(2)	351,611	D
Voting Common Stock	02/11/2026		S		241(1)	D	$18	351,370	D
Voting Common Stock								31,672	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MapLight Therapeutics (MPLT) director Robert C. Malenka report?

Robert C. Malenka reported selling shares of MapLight Therapeutics voting common stock. He sold 6,622 shares on February 10, 2026 and 241 shares on February 11, 2026, with the sales linked to tax obligations from restricted stock unit settlements.

How many MapLight Therapeutics (MPLT) shares did Robert C. Malenka sell and at what prices?

Malenka sold 6,622 shares at a weighted average price of $18.12 and 241 shares at $18.00. The larger sale involved multiple trades between $18.00 and $18.41, as disclosed in a weighted-average price footnote describing the transaction range.

Why did MapLight Therapeutics (MPLT) director Robert C. Malenka sell shares?

The sales were made to cover tax obligations from the settlement of restricted stock unit awards. Each restricted stock unit corresponds to one share of common stock, and selling a portion of the shares helped satisfy the related tax liabilities arising from this equity compensation event.

How many MapLight Therapeutics (MPLT) shares does Robert C. Malenka own after these transactions?

After the reported sales, Malenka directly owned 351,370 shares of voting common stock. He also indirectly held 31,672 shares through the Robert C. Malenka Living Trust, where he is the sole trustee with both voting power and dispositive control over the trust’s shares.

What is the price range for Robert C. Malenka’s MapLight Therapeutics (MPLT) share sales?

The weighted average sale price for the 6,622-share transaction was $18.12, based on trades executed between $18.00 and $18.41. A separate 241-share sale was executed at $18.00 per share, reflecting a narrower, single-price transaction for that smaller lot.

Are Robert C. Malenka’s remaining MapLight Therapeutics (MPLT) shares subject to a lock-up?

Yes, the remaining securities are subject to a lock-up agreement tied to the company’s initial public offering. Under this agreement, he agreed, with certain exceptions, not to sell or transfer shares for 180 days after the final IPO prospectus dated October 26, 2025.